The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Effects of the Antacids in Didanosine Tablets on Dapsone Pharmacokinetics

Jan Sahai, PharmD; Gary Garber, MD; Keith Gallicano, PhD; Linda Oliveras, BSc; and D. William Cameron, MD
[+] Article, Author, and Disclosure Information

From Ottawa General Hospital, Ottawa, Ontario, Canada. Grant Support: By a grant from the Burroughs-Wellcome Positive Action Program, Ontario Ministry of Health. Dr. Cameron is an Ontario Ministry of Health Career Scientist (#02984). Analytical development was supported in part by a grant-in-aid from Wyeth-Ayerst. Requests for Reprints: Jan Sahai, PharmD, Clinical Investigation Unit, Ottawa General Hospital, 501 Smyth Road, Ottawa K1H 8L6, Ontario, Canada. Current Author Addresses: Dr. Sahai: Clinical Investigation Unit, Ottawa General Hospital, 501 Smyth Road, Ottawa K1H 8L6, Ontario, Canada.

Copyright ©2004 by the American College of Physicians

Ann Intern Med. 1995;123(8):584-587. doi:10.7326/0003-4819-123-8-199510150-00003
Text Size: A A A

Objective: To investigate 1) the effects of the magnesium-aluminum antacids in didanosine tablets on dapsone absorption in healthy volunteers and 2) the effects of the antacid formulation of active didanosine tablets on dapsone pharmacokinetics in patients seropositive for human immunodeficiency virus (HIV).

Design: Two separate, randomized, two-period, two-treatment, crossover studies with a 21-day washout period between treatments.

Setting: Clinical investigation unit of a university hospital.

Participants: Six healthy men and six HIV-positive men.

Measurements: Serial dapsone plasma concentrations were measured when dapsone, 100 mg, was administered alone and with either the third of four doses of didanosine placebo tablets (group 1) or the 27th of 28 doses of active didanosine tablets (group 2). In each study, pharmacokinetic variables were determined using noncompartmental methods and compared by analysis of variance.

Results: When dapsone was administered alone, pharmacokinetic variables did not significantly differ from those with dapsone given in either combination (P > 0.10 for all comparisons).

Conclusions: Didanosine, antacids, and other excipients in the currently used didanosine chewable tablets did not significantly affect plasma concentrations of dapsone.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $32.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Journal Club
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.